-The Hindu Ties up with IIT-Kharagpur to gauge happiness levels Happiness, its pursuit and examining its essential nature have been considered the domain of philosophy, an ephemeral rather than tangible value. The Madhya Pradesh government, however, has tasked the Indian Institute of Technology-Kharagpur with finding a quantifiable answer to that eternal question — what constitutes happiness and how happy are people really. The State government had, in July last year, set up the...

-The Indian Express Responding to specific queries on the issue, Bhupendra Singh, NPPA chairman, told The Indian Express that “examination of hospital records is in process”. AFTER the National Pharmaceutical Pricing Authority (NPPA) in February ordered a cap on the prices of coronary stents and directed hospitals to issue separate bills specifying their cost, the drug pricing watchdog has started receiving consumer complaints against hospitals which are allegedly hiking the prices...

-The Telegraph New Delhi: The government's price cap on coronary stents has not deterred the health-care industry from continuing to offer hospitals profit opportunities of tens of thousands of rupees on other kinds of stents, concerned doctors and health-care industry representatives said.     The National Pharmaceutical Pricing Authority (NPPA), the government's price regulator, had on February 15 imposed a cap of about Rs 30,000 on coronary stents. But hospitals can continue to...

-The Times of India NEW DELHI: The Supreme Court said on Monday that a senior police officer, who has been granted a fixed tenure, can't be removed or transferred midway on the whims and fancies of the Executive, and quashed the Kerala government's decision to remove senior IPS officer T P Senkumar as DGP before completion of his two-year tenure. Holding that political interference in police administration could shake people's confidence in...

-The Telegraph New Delhi: Regulatory efforts to get doctors in India to prescribe medicines only through their generic names, initiated about 15 years ago, will need to overcome legal challenges and resistance from sections of doctors and the pharmaceutical industry, experts said. Senior pharmacologists and industry analysts have also said it will be misleading to presume that prescriptions with generic names will automatically translate into lower medicine bills for patients as studies...